Top

01-03-2017 | Glioblastoma multiforme | Article

Multilesion glioblastoma multiforme in the modern chemo-radiotherapy era: an analysis of pattern of failure and overall survival

Journal: Journal of Radiation Oncology

Authors: Daniel M. Trifiletti, Colin Hill, Allison Garda, Suraj Kabadi, Neil R. Shah, Jason P. Sheehan, James M. Larner

Publisher: Springer Berlin Heidelberg

Abstract

Purpose/objectives

We sought to evaluate the pattern of disease progression and survival of patients with multilesion glioblastoma (GBM) in a modern patient cohort.

Methods/materials

We retrospectively collected the clinical data of patients over 2004–2014 with newly diagnosed GBM. Following resection (or biopsy), all patients received radiotherapy to 60 Gy in 30 fractions with concurrent and adjuvant temozolomide. Preoperative MRIs were reviewed by a single diagnostic radiologist blinded to treatment outcomes and categorized as single focus or multilesion (multifocal/multicentric). Multifocal tumors were defined as noncontiguous enhancement along known neural pathways and multicentric tumors were defined as noncontiguous enhancement along disjointed pathways (i.e., different lobes). Univariate and multivariate (MVA) analyses were performed to investigate factors prognostic of overall survival.

Results

Of 155 eligible patients, 30 presented with a multilesion tumor focus (19.4%). Of the patients that developed recurrent disease before death (n = 123), the predominant pattern of failure was local (80%) and did not differ by focality (p = 0.18). Unifocal, multifocal, and multicentric tumors demonstrated similar actuarial disease progression (p = 0.12). Median survival was inferior in patients with multifocal and multicentric disease compared to unifocal disease (11.5, 7.1, and 18.0 months, respectively, p = 0.009). On MVA, factors prognostic of overall survival included age ≥70 (HR 3.89, p < 0.001), MGMT promoter hypermethylation (HR 0.21, p = 0.004), IDH1/2 mutation status (p = 0.044), and multicentric tumors (HR 7.18, p = 0.002). Extent of tumor resection did not impact OS (p = 0.308).

Conclusions

We identified unifocal, multifocal, and multicentric GBM entities with differing overall survival following modern chemo-radiotherapy techniques despite similar pattern of disease progression.

Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466CrossRefPubMed

National Comprehensive Cancer Network Clinical Practice Guidelines: Central Nervous System Cancers v1.2016, Available at: http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf, Accessed 1 Dec. 2016

Paulsson AK, Holmes JA, Peiffer AM et al (2014) Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. J Neuro-Oncol 119:429–435CrossRef

Patil CG, Yi A, Elramsisy A et al (2012) Prognosis of patients with multifocal glioblastoma: a case-control study. J Neurosurg 117:705–711CrossRefPubMed

Showalter TN, Andrel J, Andrews DW et al (2007) Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys 69:820–824CrossRefPubMed

Thomas RP, Xu LW, Lober RM et al (2013) The incidence and significance of multiple lesions in glioblastoma. J Neuro-Oncol 112:91–97CrossRef

Hassaneen W, Levine NB, Suki D et al (2011) Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article. Journal of Neurosurgery 114:576–584CrossRefPubMed

Lawrence YR, Mishra MV, Werner-Wasik M et al (2012) Improving prognosis of glioblastoma in the 21st century: who has benefited most? Cancer 118:4228–4234CrossRefPubMed

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed

10.

Armstrong TS, Wefel JS, Wang M et al (2013) Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol 31:4076–4084CrossRefPubMedPubMedCentral

11.

Li J, Wang M, Won M et al (2011) Validation and simplification of the radiation therapy oncology group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 81:623–630CrossRefPubMed

12.

Michaelsen SR, Christensen IJ, Grunnet K et al (2013) Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. BMC Cancer 13:402CrossRefPubMedPubMedCentral

13.

Stark AM, van de Bergh J, Hedderich J et al (2012) Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients. Clin Neurol Neurosurg 114:840–845CrossRefPubMed

14.

Fekete B, Werlenius K, Orndal C, et al. 2015 Prognostic factors for glioblastoma patients—a clinical population-based study. Acta Neurologica Scandinavica

15.

Tanaka S, Meyer FB, Buckner JC et al (2013) Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. J Neurosurg 118:786–798CrossRefPubMed

16.

Scott JG, Suh JH, Elson P et al (2011) Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. Neuro-Oncology 13:428–436CrossRefPubMedPubMedCentral

17.

Shakur SF, Bit-Ivan E, Watkin WG et al (2013) Multifocal and multicentric glioblastoma with leptomeningeal gliomatosis: a case report and review of the literature. Case Rep Med 2013:132679PubMedPubMedCentral

18.

Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198CrossRefPubMed

19.

Itakura H, Achrol AS, Mitchell LA, et al. Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities. Science Translational Medicine 2015;7:303ra138.